PTGS2 and breast carcinoma: Using CRISPR/Cas9 gene editing tools and preclinical models of breast cancer, we functionally validated the identified genes and addressed their roles and contributions to (1) breast cancer metastasis and (2) breast tumor resistance to COX-2 selective inhibitor, celecoxib.